vTv Therapeutics (VTVT) Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VTVT shares.
View VTVT analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued twelve-month price targets for vTv Therapeutics' stock. Their VTVT share price forecasts range from $2.00 to $6.00. On average, they anticipate the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 406.3% from the stock's current price.
View analysts price targets for VTVT or view top-rated stocks among Wall Street analysts.

vTv Therapeutics' stock was trading at $0.6628 at the beginning of the year. Since then, VTVT shares have increased by 19.2% and is now trading at $0.79.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our VTVT earnings forecast.

vTv Therapeutics Inc. (NASDAQ:VTVT) issued its earnings results on Thursday, May, 11th. The biotechnology company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.02.

Based on aggregate information from My MarketBeat watchlists, some companies that other vTv Therapeutics investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Onconova Therapeutics (ONTX), Vaxart (VXRT), Agile Therapeutics (AGRX) and Idera Pharmaceuticals (IDRA).

(VTVT) raised $125 million in an initial public offering (IPO) on Thursday, July 30th 2015. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."

Shares of VTVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VTVT stock can currently be purchased for approximately $0.79.

vTv Therapeutics (NASDAQ:VTVT) has a market capitalization of $82.62 million and generates $2.02 million in revenue each year. The biotechnology company earns $-19,160,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis.

vTv Therapeutics' mailing address is 3980 PREMIER DR SUITE 310, HIGH POINT NC, 27265. The official website for the company is www.vtvtherapeutics.com. The biotechnology company can be reached via phone at (336) 841-0300, via email at ir@vtvtherapeutics.com, or via fax at 336-841-0310.